VOGX
Vogenx, Inc.
Healthcare — Biotechnology
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
None
$20.06
$-2.73 (-11.98%)
Price History
52-Week Range
Sign in to add VOGX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $210.25M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.20 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.65 |
| 52-Week Low | $12.95 |
| 50-Day Avg | $13.96 |
| 200-Day Avg | $13.96 |
| Avg Volume | 267.4K |
| Volume | 11.9K |
Performance Analysis
NEUTRALVOGX presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($16.65), which may indicate limited upside.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 17, 2026 15:42 UTC
Back to Screener Export Report